share_log

Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38

Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38

Evercore ISI集團維持Akero Therapeutics的跑贏大盤,將目標股價下調至38美元
Benzinga ·  05/15 09:17

Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price target from $50 to $38.

Evercore ISI集團分析師麗莎·貝科維持Akero Therapeutics(納斯達克股票代碼:AKRO)的跑贏大盤,並將目標股價從50美元下調至38美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論